GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioton SA (OTCPK:BOIOF) » Definitions » Valuation Rank

Bioton (Bioton) Valuation Rank


View and export this data going back to . Start your Free Trial

What is Bioton Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Bioton Valuation Rank Related Terms

Thank you for viewing the detailed overview of Bioton's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Bioton (Bioton) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioton SA (OTCPK:BOIOF) » Definitions » Valuation Rank
Comparable Companies
WAR:SVE WAR:MAB WAR:MOC WAR:BCX WAR:PTG WAR:CTX WAR:URT WAR:PHR WAR:RDG WAR:PUR OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XKRX:068270 BNTX ALNY
Traded in Other Exchanges
BIO:Poland 7U5:Germany
Address
Ul. Staro?ci?ska 5, Warszawa, POL, 02-516
Website
http://www.bioton.pl
Bioton SA is a Poland based company engaged in the principal business activity of manufacturing medicines and pharmaceutical preparations and production of pharmaceutical substances. The products of the company include recombinant human insulin in pharmaceutical substance form and as preparations for injections; glimepiride, an oral hypoglycemic drug; and metformin, an oral hypoglycemic drug. Its products line focuses on diet supplements, products for particular nutritional uses and cosmetics dedicated to patients with certain health problems. The group operates in Poland and internationally, of which majority of the revenue is derived from Poland.